Sub-Total: $0.00
New Era in the Lipid Lowering Treatment with PCSK9 Inhibitors (Evolocumab and Alirocumab) in Patients with Atherosclerotic Cardiovascular Disease and Familial Hypercholesterolemia
Complimentary
Related products
-
Ocular Surface Disease: Pathophysiology, Evaluation, Management with Topical Agents, and Neuromodulation
Read more -
New Paradigms for Treatment and Management of Retinal Vein Occlusion (RVO)
Read more -
Cataracts: Advances in Imaging, Intraocular Lenses, and Surgical Procedures
Read more -
Novel Treatment and Management Options for Chronic Idiopathic Constipation
Read more
